Determinants of buprenorphine treatment for opioid dependence

Journal of Substance Abuse Treatment

Volumn 46, Issue 3, 2014, Pages 315-319

  Murphy, Sean M ^a   Fishman, Paul A ^b   McPherson, Sterling ^c   Dyck, Dennis G ^a   Roll, John R ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Buprenorphine; Opioid dependence; Treatment determinants

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; ALCOHOLISM; ALTERNATIVE MEDICINE; ANXIETY; ARTICLE; CHRONIC PAIN; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; FEMALE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SERVICE; HEALTH STATUS INDICATOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; OPIATE ADDICTION; PATIENT EDUCATION; PHYSICIAN; PRIORITY JOURNAL; PROGRAM COST EFFECTIVENESS; RETROSPECTIVE STUDY; SOCIAL ASPECT; TRAINING; TREATMENT DETERMINANT;

BUPRENORPHINE; OPIOID DEPENDENCE; TREATMENT DETERMINANTS;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES;

EID: 84892483977     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2013.09.003     Document Type: Article

References (41)

1. Albright J., Ciaverelli R., Essex A., Tkacz J., Ruetsch C. Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. Journal of Addiction Medicine 2010, 4(4):197-203. 10.1097/ADM.0b013e3181c816f3.
2. Amato L., Davoli M., Ferri M., Gowing L., Perucci C.A. Effectiveness of interventions on opiate withdrawal treatment: An overview of systematic reviews. Drug and Alcohol Dependence 2004, 73(3):219-226. 10.1016/J.Drugalcdep.2003.11.002.
3. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. American Journal of Psychiatry 1999, 156(11):1758-1764.
4. Arora S., Kalishman S., Dion D., Som D., Thornton K., Bankhurst A., Yutzy S. Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care. Health Affairs 2011, 30(6):1176-1184. 10.1377/hlthaff.2011.0278.
5. Barnett P.G., Rodgers J.H., Bloch D.A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001, 96(5):683-690.
6. Baxter J.D., Clark R.E., Samnaliev M., Leung G.Y., Hashemi L. Factors associated with Medicaid patients' access to buprenorphine treatment. Journal of Substance Abuse Treatment 2011, 41(1):88-96. 10.1016/j.jsat.2011.02.002.
7. Boyd C.J., Teter C.J., West B.T., Morales M., McCabe S.E. Non-medical use of prescription analgesics: A three-year national longitudinal study. Journal of Addictive Diseases 2009, 28(3):232-242. 10.1080/10550880903028452.
8. Clark R.E., Samnaliev M., Baxter J.D., Leung G.Y. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs 2011, 30(8):1425-1433. 10.1377/hlthaff.2010.0532.
9. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug and Alcohol Dependence 2006, 81(2):103-107. 10.1016/J.Drugalcdep.2005.05.009.
10. Cunningham C.O., Kunins H.V., Roose R.J., Elam R.T., Sohler N.L. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. Journal of General Internal Medicine 2007, 22(9):1325-1329. 10.1007/s11606-007-0264-7.
11. Denisco R.A., Chandler R.K., Compton W.M. Addressing the intersecting problems of opioid misuse and chronic pain treatment. Experimental and Clinical Psychopharmacology 2008, 16(5):417-428. 10.1037/A0013636.
12. Doran C. Economic evaluation of interventions for illicit opioid dependence: A review of evidence 2007, 1-44. World Health Organization.
13. Drug Enforcement Administration.(DEA) Department of Justice DEA Registration File Retrieved from. http://www.ntis.gov/products/dea.aspx.
14. Fishman, P. A., Murphy, S. M., McPherson, S., Dyck, D. G., & Roll, J. R. (2013). Impact of buprenorphine on the cost of treatment for opioid dependence. Under review. Group Health Research Institute, Seattle, WA.
15. Gunderson E.W., Fiellin D.A., Levin F.R., Sullivan L.E., Kleber H.D. Evaluation of a combined online and in person training in the use of buprenorphine. Substance Abuse: official Publication of the Association for Medical Education and Research in Substance Abuse 2006, 27(3):39-45. 10.1300/J465v27n03_06.
16. Hall A.J., Logan J.E., Toblin R.L., Kaplan J.A., Kraner J.C., Bixler D., Paulozzi L.J. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA-Journal of the American Medical Association 2008, 300(22):2613-2620.
17. Johns Hopkins The Johns Hopkins ACG System Retrieved from. http://www.acg.jhsph.org/index.php.
18. Kinsman D., Blaser J. Joint principles of a patient-centered medical home released by organizations representing more than 300,000 physicians Retrieved from. http://www.acponline.org/pressroom/pcmh.htm.
19. Kissin W., McLeod C., Sonnefeld J., Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. Journal of Addictive Diseases 2006, 25(4):91-103. 10.1300/J069v25n04_09.
20. Knudsen H.K., Ducharme L.J., Roman P.M., Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment 2005, 29(2):95-106. 10.1016/j.jsat.2005.05.002.
21. Kvamme E., Catlin M., Banta-Green C., Roll J., Rosenblatt R. Who prescribes buprenorphine for rural patients? The impact of specialty, location and practice type in Washington State. Journal of Substance Abuse Treatment 2013, 44(3):355-360. 10.1016/j.jsat.2012.07.006.
22. Ling W., Huber A., Rawson R.A. New trends in opiate pharmacotherapy. Drug and Alcohol Review 2001, 20(1):79-94.
23. Manchikanti L., Fellows B., Ailinani H., Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: A ten-year perspective. Pain Physician 2010, 13(5):401-435.
24. Mark T.L., Dilonardo J., Vandivort R., Miller K. Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine. Journal of Substance Abuse Treatment 2013, 44(5):481-487. 10.1016/j.jsat.2012.11.004.
25. Mark T.L., Woody G.E., Juday T., Kleber H.D. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence 2001, 61(2):195-206.
26. McCabe S.E., Teter C.J., Boyd C.J., Knight J.R., Wechsler H. Nonmedical use of prescription opioids among US college students: Prevalence and correlates from a national survey. Addictive Behaviors 2005, 30(4):789-805. 10.1016/J.Addbeh.2004.08.024.
27. Novak S., Ball J. Emergency department visits involving nonmedical use of selected pharmaceuticals. No. 23) 2006, Substance Abuse and Mental Health Services Administration, Rockville, MD.
28. Ridge G., Gossop M., Lintzeris N., Witton J., Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment 2009, 37(1):95-100. 10.1016/j.jsat.2008.09.007.
29. Rieckmann T.R., Kovas A.E., McFarland B.H., Abraham A.J. A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. Journal of Substance Abuse Treatment 2011, 41(4):374-385. 10.1016/j.jsat.2011.05.005.
30. Rosenblatt R.A. Project ROAM: Overview Retrieved from. http://depts.washington.edu/fammed/roam.
31. Simoens S., Ludbrook A., Matheson C., Bond C. Pharmaco-economics of community maintenance for opiate dependence: A review of evidence and methodology. Drug and Alcohol Dependence 2006, 84(1):28-39. S0376-8716(05)00403-5[pii]10.1016/j.drugalcdep.2005.12.009.
32. Substance Abuse and Mental Health Services Administration National Household Survey on Drug Abuse: Main findings 1998 2000, U.S. Department of Health and Human Services, Rockville, MD.
33. Substance Abuse and Mental Health Services Administration Good news: Ecstasy going down, but prescription drug abuse up 2003, U.S. Department of Health and Human Services, Rockville, MD.
34. Substance Abuse and Mental Health Services Administration Heroin and other opiate admissions to substance abuse treatment: The TEDS report 2009, U.S. Department of Health and Human Services, Rockville, MD.
35. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National findings (office of applied studies, NSDUH series H-36, HHS publication no. SMA 09-4434) 2009, U.S. Department of Health and Human Services, Rockville, MD.
36. Substance Abuse and Mental Health Services Administration The Drug Addiction Treatment Act of 2000 (DATA 2000) Retrieved from. http://www.buprenorphine.samhsa.gov/.
37. Thomas C.P., Reif S., Haq S., Wallack S.S., Hoyt A., Ritter G.A. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatric Services 2008, 59(8):909-916. doi:59/8/909 [pii]10.1176/appi.ps.59.8.909.
38. U.S.Food and Drug Administration Drug and Biologic Approval Reports Retrieved May 26, 2013, from. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ANDAGenericDrugApprovals/ucm189606.htm.
39. Walley A.Y., Alperen J.K., Cheng D.M., Botticelli M., Castro-Donlan C., Samet J.H., Alford D.P. Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Internal Medicine 2008, 23(9):1393-1398. 10.1007/S11606-008-0686-X.
40. Washington State Department of Health 2000 RUCA codes by 2006 Zip Code Retrieved from. http://www.doh.wa.gov/hsqa/ocrh/har/hcresrch.htm.
41. Wesson D.R., Smith D.E. Buprenorphine in the treatment of opiate dependence. Journal of Psychoactive Drugs 2010, 42(2):161-175.